RESUMO
Twenty patients with mycosis fungoides and four with Sézary's syndrome were treated with 13-cis-retinoic acid as single therapy in an initial dose of 1 to 2 mg per kg body weight in most cases. Complete remission in mycosis fungoides was obtained in six cases (33%) and partial remission in another ten cases (50%). No convincing response was observed in three cases, and progression of limited nodular lesions occurred in one case. In cases responding to treatment the first sign of remission was observed within two to four weeks. Our short-term experience is that the drug is effective in early as well as advanced stages of mycosis fungoides. Patients with Sézary's syndrome, however, did not respond to the same extent.
Assuntos
Micose Fungoide/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Tretinoína/uso terapêutico , Adulto , Idoso , Feminino , Humanos , Isomerismo , Isotretinoína , Masculino , Pessoa de Meia-Idade , Síndrome de Sézary/tratamento farmacológico , Fatores de TempoRESUMO
Epipodophyllotoxin (VP-16-213) was administered to 9 patients with mycosis fungoides in various stages, most of them in the advanced tumour stage. In 4 of the patients VP-16 was combined with cyclophosphamide. VP-16 alone or in combination with cyclophosphamide was capable of inducing remission initially in all cases, complete in 2, partial in 3 and improvement to a lesser degree in the remaining 5 patients, but it was unable to maintain the remission. The induced remission has to be upheld by other agents, possibly added to VP-16.
Assuntos
Ciclofosfamida/uso terapêutico , Micose Fungoide/tratamento farmacológico , Podofilotoxina/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Adulto , Idoso , Ensaios Clínicos como Assunto , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Avaliação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Podofilotoxina/administração & dosagem , Podofilotoxina/efeitos adversosRESUMO
Prednimustine, a chlorambucil ester of prednisolone, was administered orally to 5 patients with mycosis fungoides in advanced tumour stage. Partial remission was obtained in 2 of the patients. However, we do not consider the agent to be particularly advantageous for the treatment of mycosis fungoides.
Assuntos
Clorambucila/uso terapêutico , Micose Fungoide/tratamento farmacológico , Prednisolona/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Administração Oral , Idoso , Clorambucila/administração & dosagem , Clorambucila/efeitos adversos , Ensaios Clínicos como Assunto , Combinação de Medicamentos , Avaliação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prednisolona/administração & dosagem , Prednisolona/efeitos adversosRESUMO
In a double-blind study 91 patients with acne vulgaris were treated either with oral zinc sulphate (0.4 g daily) or with a placebo. Forty-eight patients received zince treatment and 43 patients placebo. Significantly better results were demonstrated in favour of zince after 12 weeks.
Assuntos
Acne Vulgar/tratamento farmacológico , Zinco/uso terapêutico , Administração Oral , Adolescente , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Masculino , Placebos , Zinco/administração & dosagemRESUMO
Thirty-nine patients with mycosis fungoides in various stages or Sézary syndrome were treated with isotretinoin and 29 with etretinate as single drug therapy. Complete remission within 2 months was obtained with isotretinoin in 8 cases (21%) and partial remission in another 15 cases (38%). Etretinate induced complete remission in 5 cases (21%) and partial remission in 11 (46%). Only 1 case with Sézary syndrome went into partial remission. The first sign of remission occurred in 2 to 4 weeks. During continued treatment remissions could not always be maintained. Isotretinoin and etretinate were considered to be of equal potency in the treatment of mycosis fungoides.
Assuntos
Etretinato/uso terapêutico , Micose Fungoide/tratamento farmacológico , Síndrome de Sézary/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Tretinoína/uso terapêutico , Toxidermias/patologia , Etretinato/efeitos adversos , Humanos , Isotretinoína , Metástase Linfática , Indução de Remissão , Tretinoína/efeitos adversosRESUMO
Thirty-three patients with frequently recurring genital herpes completed a randomized double-blind, crossover trial with oral acyclovir 200 mg 4 times a day and placebo for periods of 12 weeks. Five patients (15%) had full recurrence during acyclovir treatment and 31 (94%) while receiving placebo. The median time to first recurrence was 20 days for placebo and more than 84 days for acyclovir. It was concluded that acyclovir was well tolerated and an effective treatment to suppress the disease in selected cases of severe and frequently recurring genital herpes. However, the relapses seem to occur with the same rate as before, when the suppressive acyclovir treatment is stopped.
Assuntos
Aciclovir/uso terapêutico , Herpes Genital/tratamento farmacológico , Administração Oral , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Assistência de Longa Duração , Masculino , Pessoa de Meia-Idade , Distribuição Aleatória , RecidivaRESUMO
Combination chemotherapy with cyclophosphamide, vincristine, VP-16, adriamycin and prednisolone was given in 9 cases of mycosis fungoides in the tumor stage; 3 of these patients received COP, one received CHOP, and 5 CAVOP. Complete remission was obtained in one case and partial remission in 5, the response rate thus being 6/9. It was impossible, however, to maintain remission. The treatment was reduced or withdrawn owing to toxic effects in 4 cases. These forms of combination chemotherapy are beneficial in non-Hodgkin lymphomas but do not seem to be of value in the tumour stage of mycosis fungoides.